


IN THE CLAIMS


Please cancel without prejudice claims 18, 19 and 27-30.

Kindly replace claims 16, 17 and 26 by the following claims.

16. (amended) A method for protecting body-care and household products from photolytic degradation which comprises incorporating into a body care or household product a benzotriazole of formula




and/or a triazine compound of formula



wherein

R_1 is C_1 - C_{12} alkyl; C_1 - C_5 alkoxy; C_1 - C_5 alkoxycarbonyl; C_5 - C_7 cycloalkyl; C_6 - C_{10} aryl; aralkyl; $-SO_3M$; a



M is alkali or ammonium;

R_3 is hydrogen; C_1 - C_5 alkyl; C_1 - C_5 alkoxy; halogen; or hydroxy;

R_4 and R_5 are each independently of the other hydrogen; or C_1 - C_5 alkyl;

m is 1 or 2;

n is 0 or 1;

if $m = 1$,

R_2 is hydrogen; unsubstituted or phenyl-substituted C_1 - C_{12} alkyl; C_6 - C_{10} aryl; $-SO_3M$;

if $m = 2$,

R_2 is a direct bond; $-(CH_2)_p$; and

p is 1 to 3;


L_1 is C_1 - C_{22} alkyl, C_2 - C_{22} alkenyl or C_5 - C_7 cycloalkyl;

L_2 and L_6 are each independently of the other H, OH, halogen, C_1 - C_{22} alkyl, halomethyl;

L_3 , L_5 and L_7 are each independently of one another H, OH, OL_1 , halogen, C_1 - C_{22} alkyl, halomethyl;

L_4 is H, OH, OL_1 , halogen, C_1 - C_{22} alkyl, phenyl, halomethyl;


L_{12} is C_1 - C_{22} alkyl, phenyl C_1 - C_5 alkyl, C_5 - C_7 cycloalkyl, OL_1 or a group of formula



; and

j is 0, 1, 2 or 3.

17. (amended) A method according to claim 16, which comprises incorporating a benzotriazole of formula



wherein

R_1 is C_1 - C_5 alkyl; and

R_2 is SO_3M .

26. (amended) A method according to claim 21, wherein the preparations containing active ingredients are selected from hormone preparations, vitamin preparations, vegetable extract preparations and antibacterial preparations.

STATUS OF THE CLAIMS

Claims 16-30 were pending in this application.

Claims 18, 19, 27, 28 and 30 are withdrawn from consideration.

Claim 17 is objected to under 37 CFR 1.75(c).

Claims 16, 20-26 and 29 are rejected under 35 U.S.C. § 112, second paragraph.

Claims 16, 17, 20, 21, 24, 26 and 29 are rejected under 35 U.S.C. § 102(a) as being anticipated by Luther, US Patent 6,090,370.

Claims 16, 20-23, 25, 26 and 29 are rejected under 35 U.S.C. § 102(b) as being anticipated by Dumler et al. (GB 2,286,774).

Claims 16, 20-22, 24, 25 and 29 are rejected under 35 U.S.C. § 102(b) as being anticipated by Strobel (US Patent 3,983,132).

Claims 19 and 27-30 have been cancelled.

Claims 16, 17 and 26 have been amended.

Claims 16-18 and 20-26 are presented for reconsideration.

REMARKS

The examiner asserts on page 3 of the Office action that the application has no abstract. In the undersigned's copy the abstract is the last page, page 44. Applicants submit herewith a copy as a separate sheet.

see page 5
Responsive to the restriction requirement set forth in the previous Office action, applicants affirmed election of the claims of group I, claims 16-26 and 29 (benzotriazoles of formula 1) for examination. This election was made without traverse. Non-elected claims 19, 27, 28 and 30 have therefore been cancelled without prejudice to applicants' rights to file subsequent divisional applications to the non-elected subject matter. Inventorship is unchanged. However, claim 18 embraces a benzotriazole of formula 1 where $m = 2$, R_2 is $-CH_2-$ and R_1 is hydrogen or C_1-C_{12} alkyl (e.g. the disclosed commercial